Sub-millimetric, patient-specific brain targeting for functional neurosurgery and real-world outcomes in Parkinson’s Disease and Essential Tremor.

“La Gazette du Laboratoire” Features RebrAIn’s Breakthrough in Deep Brain Stimulation

We are pleased to announce that La Gazette du Laboratoire has featured RebrAIn for our revolutionary advancements in neurosurgical targeting for Deep Brain Stimulation (DBS).

The article highlights our collaboration with SATT Aquitaine Science Transfert and the development of our supervised AI-driven platform, OptimDBS, designed to enhance the precision and effectiveness of DBS treatments.

Learn more about how RebrAIn is transforming neurosurgery and improving patient outcomes by reading the full article here, in french.

An English translation by Google is available here.

Our latest public updates

RebrAin 2025/2026: Expanding Reach, Driving Innovation

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

Rebrain publishes OPTIVIM trial results in Neurosurgery

Rebrain publishes OPTIVIM trial results in Neurosurgery

An innovative and automated method RebrAIn’s service is based on a machine learning model trained on data from successfully treated patients. Using only a standard 3D T1 MRI, the algorithm automatically computes the stereotactic coordinates of the optimal DBS target,...